795 PHARMACEUTICAL COMPOUNDING—NONSTERILE …
tive ingredient in that preparation and furnishing pharma-specified limits and throughout its period of storage and cological activity or other direct effect in the diagnosis, use, the same properties and characteristics that it pos-cure, mitigation, treatment, or prevention of disease in sessed at the time of compounding (see Stability Considera-
Download 795 PHARMACEUTICAL COMPOUNDING—NONSTERILE …
Information
Domain:
Source:
Link to this page:
Documents from same domain
MONOGRAPHS (USP) - uspnf.com
www.uspnf.comProcedure—Transfer a sufficient portion of Test solution A and Test solution B to separate test tubes of colorless, transparent, neutralglass withaflatbaseandaninternaldia-
Stearic Acid M - uspnf.com
www.uspnf.comStage 6 Harmonization Official May 1, 2016 Stearic 1. = molecular weight of potassium hydroxide, Stearic Acid M r 56.11 NF34 Acceptance criteria: 194–212 Portions of this monograph that are national USP text, and • C. The retention times of the major peaks of the Sample are not part of the harmonized text, are marked with solution correspond …
Injections and Implanted Drug Products (Parenterals ...
www.uspnf.comLarge-volume injections for single-dose infusion, small-Aqueous vehicles—Aqueous vehicles must meet the require- volume injections, and pharmacy bulk packages (PBPs) arements of 〈151〉 or 〈85〉, whichever is specified in the mono-
1092 THE DISSOLUTION PROCEDURE: DEVELOPMENT AND …
www.uspnf.comBRIEFING 1092 The Dissolution Procedure: Development and Validation, USP 36 page 735. This general information chapter is proposed for revision by the …
Compendial Approvals for USP42-NF37 1S
www.uspnf.comCompendial Approvals for USP42-NF37 1S Category Monograph Title Monograph Section Scientific Liaison Revision
<788> PARTICULATE MATTER IN INJECTIONS - uspnf.com
www.uspnf.comsize. The definition for particle-free water is provided in Reagent Specifications under Reagents, Indicators and Solution section. The apparatus is calibrated using dispersions of …
DISSOLUTION - USP-NF
www.uspnf.comRevision Bulletin 4 〈711〉 Dissolution Official February 1, 2012 flow rates of 4, 8, and 16 mL per minute. It must deliver a constant flow (±5% of the nominal flow rate); the flow pro-file is sinusoidal with a pulsation of 120±10 pulses per
General Notices and Requirements - uspnf.com
www.uspnf.com4 General Notices USP 32 3.10.10. Applicability of Standards to Drug Products, Drugarticle.For general requirements relating to specific monograph Substances, and Excipients sections, see section 5, Monograph Components. The applicable USP or NF standard applies to any article mar-Because monographs may not provide standards for all relevant keted in the United States that (1) is …
Levetiracetam Tablets - uspnf.com
www.uspnf.comRevision Bulletin 2 Levetiracetam Official May 1, 2011 Sample solution: Pass a portion of the solution under test Mode: LC through a suitable filter. Dilute an aliquot with Medium to Detector: UV 200 nm obtain a concentration similar to that of the Standard Column: 4.6-mm × 25-cm; 4-µm packing L1 solution.
Residual Solvents: ICH Q3C Impurities: Residual Solvents
www.uspnf.comheadspace analysis, solid-phase microextraction, and direct injection of solution containing bulk drug substance or drug product into the gas chromatograph. zIn conclusion, gas chromatograph-based procedures will continue to dominate residual solvent testing because of its specificity for
Related documents
Polymorphism—A Critical Consideration in Pharmaceutical ...
cmbe.engr.uga.edu• Pharmaceutical solids may be crystals, crystal solvates or hydrates, crystal desolvated solvates or dehydrated hydrates, or amorphous solids ... ence, ritonavir, the active ingredient in Norvir Capsules (Abbott), was identified as the key component in various protease inhibitor cocktails (combination therapies) used
<1151> PHARMACEUTICAL DOSAGE FORMS - DrugFuture
www.drugfuture.comto administer the active pharmaceutical ingredient (API). ItDisintegration 〈701〉, and Drug Release 〈724〉). discusses general principles involved in the manufacture or compounding of these dosage forms and recommendations Bioavailability (see also In Vitro and In Vivo Evaluation of for proper use and storage.
ISSN: 2231 Stability Testing of Pharmaceutical Products
www.japsonline.comracemization etc. that occur in the pharmaceutical products may lead to the formation of degradation product, loss of potency of active pharmaceutical ingredient (API), loss of excipient activity like antimicrobial preservative action and antioxidants etc. (Carstensen et al., 2000). Stability of a pharmaceutical product can
JCPRC5 - Pharmaceutical Research
www.jocpr.comThe purpose of an identification or identity test is to verify the identity of the active pharmaceutical ingredient (API) in the pharmaceutical tablet. This test should be able to discriminate between compounds of closely related structures that are likely to be present [12]. Assay This test determines the strength or content of the API in the ...
DEFINITION OF ACTIVE PHARMACEUTICAL INGREDIENT
www.who.int"active pharmaceutical ingredient (API) A substance used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring,
Annex 2 W HO good manufacturing practices for active ...
www.who.intpharmaceutical ingredients 1. Introduction 1.1 Objective 1.2 Regulatory applicability 1.3 Scope 2. Quality management 2.1 Principles 2.2 Responsibilities of the quality unit(s) 2.3 Responsibility for production activities 2.4 Internal audits (self-inspection) 2.5 Product quality review 3. Personnel 3.1 Personnel qualifi cations 3.2 Personnel ...